Mavelertinib is a selective, oral, irreversible EGFR tyrosine kinase inhibitor (EGFR TKI) with IC50 values of 5, 4, 12, and 3 nM for Del, L858R, T790M/L858R, and T790M/Del mutations respectively. It is used in non-small cell lung cancer (NSCLC) research.